The Java Community Process formally launches development of Java SE 28, with Project Valhalla once again positioned as the release's most closely watched feature.

SAN FRANCISCO and SUZHOU, China, May 21, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Shane O'Kelly, the CEO of Advance Auto Parts, Inc. (NYSE: AAP), recently spoke about the ...

Patients with previously untreated, locally advanced, unresectable or metastatic triple-negative breast cancer who are not candidates for inhibitors of programmed cell death protein 1 (PD-1) or ...

NEW YORK, Sept. 23, 2025 (GLOBE NEWSWIRE) -- IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulatory, off-the-shelf therapeutic cancer vaccines, today ...

Abstract Security, the leader in streaming-first security data operations, is unveiling the PAINT (Partnerships, Alliances, and INTegrations) Partner Program, a new initiative that supercharges ...

Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...

WhatsApp has introduced Advanced Chat Privacy, a feature that builds on its end-to-end encryption to keep your messages as private as possible by keeping chats in the ...

Jakarta EE, a working group hosted by the Eclipse Foundation, today announced the general availability of the Jakarta EE 11 Platform, the latest version of its enterprise Java platform. The new ...

Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with content, and download exclusive resources. In this episode, Heroku co-founder and Ink & ...

A retrospective study of anlotinib plus third-generation EGFR-TKIs in advanced non-small cell lung cancer with gradual or oligo progression after EGFR-TKIs treatment (ALTER-L058). This is an ASCO ...